Can Mounjaro Cause Urinary Tract Infections?

Does tirzepatide list urinary tract infections as a side effect?

The short answer is no. The UK Summary of Product Characteristics for Mounjaro, published on the electronic Medicines Compendium, does not include urinary tract infections among common, uncommon, or rare adverse reactions. The large SURMOUNT trials — which enrolled thousands of adults across multiple dose groups — reported a side-effect profile led by gastrointestinal symptoms rather than urinary ones. Nausea, vomiting, diarrhoea, constipation, and reflux were the dominant concerns, particularly in the early weeks of treatment or after a dose increase.

The NHS patient information page for tirzepatide reflects this, listing GI effects as the primary category to watch for. If you search the clinical literature hoping to find a causal link between Mounjaro and UTIs, the published trial data simply does not support one. That does not mean every person's experience is identical, but it does mean there is no pharmacological signal pointing to a direct cause.

Indirect connections, however, are worth taking seriously. The mechanism matters here: Mounjaro slows gastric emptying and reduces appetite, and for some people that translates to reduced fluid intake without them noticing. Mild dehydration is a well-established predisposing factor for UTIs, because concentrated urine creates an environment bacteria thrive in. If you find you are drinking less than usual, particularly in the first few weeks of treatment, that is worth correcting.

Why might some people notice UTI symptoms while taking Mounjaro?

There are a few plausible indirect pathways, and it helps to think about them honestly rather than dismissing the experience of anyone who has noticed a pattern.

First, the dehydration question already raised. Mounjaro can cause significant fluid losses in people who experience vomiting or diarrhoea, especially around dose increases. The NHS guidance on weight management injections highlights dehydration as a risk to monitor during treatment. Drinking enough water throughout the day is practical advice, but it matters more on tirzepatide than it might otherwise.

Second, for the significant proportion of people using Mounjaro to treat type 2 diabetes alongside weight management, diabetes itself raises UTI risk. High blood glucose promotes bacterial growth in the urinary tract. As Mounjaro improves glycaemic control, this risk may actually reduce over time, but in the short term someone managing both conditions should not automatically attribute a UTI to the medicine when the underlying condition is a more established cause.

Third, there is the straightforward statistical reality that people on long-term treatment for any condition are more likely to notice and report symptoms they might otherwise have ignored. UTIs are common in the general adult population, particularly in women. Some of those occurrences will simply coincide with Mounjaro treatment without any causal link at all, and you can read more about whether Mounjaro can cause UTIs in the dedicated guide our prescribers put together on this question. A question our prescribers hear fairly regularly is whether a symptom is the medicine or something else entirely, and the honest answer is that coincidence is often the most likely explanation.

When should you contact your prescriber or GP about urinary symptoms?

Symptoms that should not wait: burning or stinging when you pass urine, needing to go much more frequently than usual, cloudy or strong-smelling urine, pain in your lower abdomen or back, or fever and chills alongside any of the above. These are symptoms of a UTI regardless of whether you are on Mounjaro, and they need assessment and likely antibiotic treatment from your GP or another clinician. They are not something to manage by adjusting your tirzepatide dose or stopping treatment without advice.

If you are unsure whether your symptoms are related to the medicine, that is exactly the kind of question to raise with our clinical team through the support contact page. nume's prescribers provide aftercare seven days a week, and a message is always better than guessing.

It is also worth noting that if you experience severe or persistent abdominal pain during Mounjaro treatment, that is a different and more urgent concern. The MHRA has highlighted acute pancreatitis as an infrequent but serious potential effect of GLP-1 medicines generally, and severe stomach pain radiating to the back, with or without vomiting, warrants immediate medical attention. For a broader picture of the range of symptoms Mounjaro can and cannot cause, the overview of what Mounjaro can cause covers the full SmPC-listed profile.

Staying well-hydrated on Mounjaro: a practical note

Hydration sits at the practical centre of this topic. The advice is not complicated, but it is easy to overlook when nausea reduces your appetite for food and drink alike. Keeping a glass of water visible on the kitchen side helps, as does having something with you when you go out. The 12pm order cut-off for same-day dispatch is something our team thinks about daily, but the habit most useful for patients on tirzepatide is simpler: small, regular sips of water rather than waiting until you feel thirsty.

For context on tirzepatide's mechanism and how it compares with other treatments, the tirzepatide overview explains the dual GIP and GLP-1 receptor action in detail. If you are considering treatment for the first time or have questions about whether you are suitable, the Mounjaro treatment page covers eligibility in plain terms, and you can also read about whether Mounjaro can cause IBS-like symptoms, which shares some of the same GI overlap worth understanding.

Mounjaro is a prescription-only medicine. Whether it is right for you depends on a clinical assessment that looks at your full health picture. People sometimes also ask whether Mounjaro is a placebo, a question our prescribers address in detail given how striking the clinical results can seem at first glance. If you have been wondering about this question or others like it, speaking to a prescriber is always the most reliable next step. You can start your free consultation through our treatment page, where a GPhC-registered prescriber reviews your case the same day.